Skip to content
value.today

Tocagen Inc

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2007
Total raised
$143 M
10 rounds on record
Latest round
$25 M
Jul 2023
First round on record
Sep 2008
Today
Private
No later event on record

Funding rounds

10 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Tocagen Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2023$25 MNo. 10$10 to $50 million

Tocagen Inc: Raise no. 10, Jul 2023

Investors in this round

27 investors had bought by the notice of Aug 9, 2023: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Antony Riley · Executive Officer
  • Hubert Chen · Executive Officer
  • Paul Wagner · Executive Officer, Director
  • Barbara Fink · Director
  • David Gryska · Director
  • Donald Williams · Director
  • Lawrence Eichenfield · Director
  • Scott Brun · Director
  • Stephen Doberstein · Director
  • Steven Kornfeld · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul A. Wagner, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 9, 2023. Read the notice at the SEC.

equity, optionsSEC
Nov 2016$11 MNo. 9$10 to $50 million

Tocagen Inc: Raise no. 9, Nov 2016

Investors in this round

107 investors had bought by the notice of Mar 13, 2017: 107 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $13 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Mark J Foletta · Executive Officer
  • Martin J Duvall · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director
  • David R. Parkinson · Director
  • Faheem M. Hasnain · Director
  • Franklin M. Berger · Director
  • Lori R. Kunkel · Director
  • Paul R. Schimmel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Mark Foletta, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 13, 2017. Read the notice at the SEC.

debt, optionsSEC
May 2013$46 MNo. 8$10 to $50 million

Tocagen Inc: Raise no. 8, May 2013

Investors in this round

250 investors had bought by the notice of Oct 22, 2015: 250 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$46 M of $50 M offered; $4 M still to sell
Smallest investment taken
$10,500
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$13,964
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director
  • David R. Parkinson · Director
  • Faheem M. Hasnain · Director
  • Franklin M. Berger · Director
  • Lori R. Kunkel · Director
  • Paul R. Schimmel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Newbridge Securities Corporation (CRD 104065) · Fort Lauderdale, FloridaSold in all US states

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Oct 22, 2015. Read the notice at the SEC.

equitySEC
Feb 2012$9 MNo. 7$2 to $10 million

Tocagen Inc: Raise no. 7, Feb 2012

Investors in this round

32 investors had bought by the notice of Dec 5, 2012: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $15 M offered; $6 M still to sell
Smallest investment taken
$200,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 5, 2012. Read the notice at the SEC.

equitySEC
Dec 2010$15 MNo. 6$10 to $50 million

Tocagen Inc: Raise no. 6, Dec 2010

Investors in this round

88 investors had bought by the notice of Nov 8, 2011: 88 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $28 M offered; $13 M still to sell
Smallest investment taken
$110,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Nov 8, 2011. Read the notice at the SEC.

equitySEC
Jun 2010$5 MNo. 5$2 to $10 million

Tocagen Inc: Raise no. 5, Jun 2010

Investors in this round

43 investors had bought by the notice of Oct 5, 2010: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 5, 2010. Read the notice at the SEC.

equitySEC
Feb 2010$8 MNo. 4$2 to $10 million

Tocagen Inc: Raise no. 4, Feb 2010

Investors in this round

75 investors had bought by the notice of Mar 5, 2010: 75 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series D Financing”

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 5, 2010. Read the notice at the SEC.

equitySEC
Jan 2010$3 MNo. 3$2 to $10 million

Tocagen Inc: Raise no. 3, Jan 2010

Investors in this round

2 investors had bought by the notice of Feb 26, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offer by the Issuer of up to 1,578,948 shares of Series C-1 Preferred Stock at $1.90 per share.”

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D, newest notice filed Feb 26, 2010. Read the notice at the SEC.

equitySEC
Jun 2009$9 MNo. 2$2 to $10 million

Tocagen Inc: Raise no. 2, Jun 2009

Investors in this round

100 investors had bought by the notice of Nov 23, 2009: 100 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $10 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Issuer may issue up to 6,250,000 shares of Series C Preferred Stock at $1.60 per share.”

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Nov 23, 2009. Read the notice at the SEC.

equitySEC
Sep 2008$11 MNo. 1$10 to $50 million

Tocagen Inc: Raise no. 1, Sep 2008

Investors in this round

99 investors had bought by the notice of Jun 2, 2009: 99 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for Tocagen Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series B Preferred Stock
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$29,750
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Dennis Berman · Executive Officer, Director
  • Douglas Jolly · Executive Officer
  • Harry Gruber · Executive Officer, Director
  • Thomas Darcy · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Skyway Advisors, LLC (CRD 124630) · Tampa, FlSold in no state named
  • Yoram Kinberg, YK Consulting · New York, NySold in no state named

Remarks in the notice

  • On the amounts: “Issuer may issue up to 9,000,000 shares of Series B Preferred Stock at $1.25 per share.”

Signed by Thomas E. Darcy, Chief Financial Officer. Source: SEC Form D and 2 amendments, newest notice filed Jun 2, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Tocagen Inc chose not to state its revenue in its newest notice of a funding round (Aug 2023).

    SEC Form D · Aug 2023

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2023

That is all the official record says: Tocagen Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in Tocagen Inc
InvestorKindAmountRoundRoleSource
Paul SchimmelPersonnot statednot statedHeld Series H preferred stock, director (Form 3, 2017)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 10 rounds above had up to 250 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Tocagen Inc
NameRoleNamed in
Antony RileyExecutive officerAug 2023
Hubert ChenExecutive officerAug 2023
Paul WagnerExecutive officerAug 2023
Dennis BermanExecutive officerMar 2017
Douglas JollyExecutive officerMar 2017
Harry GruberExecutive officerMar 2017
Mark J FolettaExecutive officerMar 2017
Martin J DuvallExecutive officerMar 2017
Thomas DarcyExecutive officerMar 2017
Barbara FinkDirectorAug 2023
David GryskaDirectorAug 2023
Donald WilliamsDirectorAug 2023
Lawrence EichenfieldDirectorAug 2023
Paul WagnerDirectorAug 2023
Scott BrunDirectorAug 2023
Stephen DobersteinDirectorAug 2023
Steven KornfeldDirectorAug 2023
David R. ParkinsonDirectorMar 2017
Dennis BermanDirectorMar 2017
Faheem M. HasnainDirectorMar 2017
Franklin M. BergerDirectorMar 2017
Harry GruberDirectorMar 2017
Lori R. KunkelDirectorMar 2017
Martin J DuvallDirectorMar 2017
Paul R. SchimmelDirectorMar 2017
Thomas DarcyDirectorMar 2017